Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2013

Open Access 01-12-2013 | Research

High mitochondria content is associated with prostate cancer disease progression

Authors: Katharina Grupp, Karolina Jedrzejewska, Maria Christina Tsourlakis, Christina Koop, Waldemar Wilczak, Meike Adam, Alexander Quaas, Guido Sauter, Ronald Simon, Jakob Robert Izbicki, Markus Graefen, Hartwig Huland, Thorsten Schlomm, Sarah Minner, Stefan Steurer

Published in: Molecular Cancer | Issue 1/2013

Login to get access

Abstract

Background

Mitochondria are suggested to be important organelles for cancer initiation and promotion. This study was designed to evaluate the prognostic value of MTC02, a marker for mitochondrial content, in prostate cancer.

Methods

Immunohistochemistry of using an antibody against MTC02 was performed on a tissue microarray (TMA) containing 11,152 prostate cancer specimens. Results were compared to histological phenotype, biochemical recurrence, ERG status and other genomic deletions by using our TMA attached molecular information.

Results

Tumor cells showed stronger MTC02 expression than normal prostate epithelium. MTC02 immunostaining was found in 96.5% of 8,412 analyzable prostate cancers, including 15.4% tumors with weak, 34.6% with moderate, and 46.5% with strong expression. MTC02 expression was associated with advanced pathological tumor stage, high Gleason score, nodal metastases (p < 0.0001 each), positive surgical margins (p = 0.0005), and early PSA recurrence (p < 0.0001) if all cancers were jointly analyzed. Tumors harboring ERG fusion showed higher expression levels than those without (p < 0.0001). In ERG negative prostate cancers, strong MTC02 immunostaining was linked to deletions of PTEN, 6q15, 5q21, and early biochemical recurrence (p < 0.0001 each). Moreover, multiple scenarios of multivariate analyses suggested an independent association of MTC02 with prognosis in preoperative settings.

Conclusions

Our study demonstrates high-level MTC02 expression in ERG negative prostate cancers harboring deletions of PTEN, 6q15, and 5q21. Additionally, increased MTC02 expression is a strong predictor of poor clinical outcome in ERG negative cancers, highlighting a potentially important role of elevated mitochondrial content for prostate cancer cell biology.
Appendix
Available only for authorised users
Literature
1.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 2013, 63: 11-30. 10.3322/caac.21166CrossRefPubMed
2.
3.
Davis RE, Williams M: Mitochondrial function and dysfunction: an update. J Pharmacol Exp Ther. 2012, 342: 598-607. 10.1124/jpet.112.192104CrossRefPubMed
4.
Fogg VC, Lanning NJ, Mackeigan JP: Mitochondria in cancer: at the crossroads of life and death. Chin J Cancer. 2011, 30: 526-539. 10.5732/cjc.011.10018PubMedCentralCrossRefPubMed
5.
Abu-Amero KK, Alzahrani AS, Zou M, Shi Y: High frequency of somatic mitochondrial DNA mutations in human thyroid carcinomas and complex I respiratory defect in thyroid cancer cell lines. Oncogene. 2005, 24: 1455-1460. 10.1038/sj.onc.1208292CrossRefPubMed
6.
Warowicka A, Kwasniewska A, Gozdzicka-Jozefiak A: Alterations in mtDNA: a qualitative and quantitative study associated with cervical cancer development. Gynecol Oncol. 2013, 129: 193-198. 10.1016/j.ygyno.2013.01.001CrossRefPubMed
7.
Gao JY, Song BR, Peng JJ, Lu YM: Correlation between mitochondrial TRAP-1 expression and lymph node metastasis in colorectal cancer. World J Gastroenterol. 2012, 18: 5965-5971. 10.3748/wjg.v18.i41.5965PubMedCentralCrossRefPubMed
8.
Qian XL, Li YQ, Gu F, Liu FF, Li WD, Zhang XM, Fu L: Overexpression of ubiquitous mitochondrial creatine kinase (uMtCK) accelerates tumor growth by inhibiting apoptosis of breast cancer cells and is associated with a poor prognosis in breast cancer patients. Biochem Biophys Res Commun. 2012, 427: 60-66. 10.1016/j.bbrc.2012.08.147CrossRefPubMed
9.
Gogvadze V, Orrenius S, Zhivotovsky B: Mitochondria as targets for cancer chemotherapy. Semin Cancer Biol. 2009, 19: 57-66. 10.1016/j.semcancer.2008.11.007CrossRefPubMed
10.
Leber B, Geng F, Kale J, Andrews DW: Drugs targeting Bcl-2 family members as an emerging strategy in cancer. Expert Rev Mol Med. 2010, 12: e28-10.1017/S1462399410001572CrossRefPubMed
11.
Indran IR, Tufo G, Pervaiz S, Brenner C: Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochimica Et Biophysica Acta-Bioenergetics. 1807, 2011: 735-745.
12.
Ambrosini-Spaltro A, Salvi F, Betts CM, Frezza GP, Piemontese A, Del Prete P, Baldoni C, Foschini MP, Viale G: Oncocytic modifications in rectal adenocarcinomas after radio and chemotherapy. Virchows Arch. 2006, 448: 442-448. 10.1007/s00428-005-0137-6CrossRefPubMed
13.
Geyer FC, de Biase D, Lambros MB, Ragazzi M, Lopez-Garcia MA, Natrajan R, Mackay A, Kurelac I, Gasparre G, Ashworth A: Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biology. Breast Cancer Res Treat. 2012, 132: 15-28. 10.1007/s10549-011-1504-4CrossRefPubMed
14.
Chen JZ, Gokden N, Greene GF, Mukunyadzi P, Kadlubar FF: Extensive somatic mitochondrial mutations in primary prostate cancer using laser capture microdissection. Cancer Res. 2002, 62: 6470-6474.PubMed
15.
Chen JZ, Kadlubar FF: Mitochondrial mutagenesis and oxidative stress in human prostate cancer. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2004, 22: 1-12. 10.1081/GNC-120037931CrossRefPubMed
16.
Jeronimo C, Nomoto S, Caballero OL, Usadel H, Henrique R, Varzim G, Oliveira J, Lopes C, Fliss MS, Sidransky D: Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene. 2001, 20: 5195-5198. 10.1038/sj.onc.1204646CrossRefPubMed
17.
Jessie BC, Sun CQ, Irons HR, Marshall FF, Wallace DC, Petros JA: Accumulation of mitochondrial DNA deletions in the malignant prostate of patients of different ages. Exp Gerontol. 2001, 37: 169-174. 10.1016/S0531-5565(01)00153-XCrossRefPubMed
18.
Kloss-Brandstatter A, Schafer G, Erhart G, Huttenhofer A, Coassin S, Seifarth C, Summerer M, Bektic J, Klocker H, Kronenberg F: Somatic mutations throughout the entire mitochondrial genome are associated with elevated PSA levels in prostate cancer patients. Am J Hum Genet. 2010, 87: 802-812. 10.1016/j.ajhg.2010.11.001PubMedCentralCrossRefPubMed
19.
Lindberg J, Mills IG, Klevebring D, Liu W, Neiman M, Xu J, Wikstrom P, Wiklund P, Wiklund F, Egevad L, Gronberg H: The mitochondrial and autosomal mutation landscapes of prostate cancer. Eur Urol. 2013, 63: 702-708. 10.1016/j.eururo.2012.11.053CrossRefPubMed
20.
Parr RL, Dakubo GD, Crandall KA, Maki J, Reguly B, Aguirre A, Wittock R, Robinson K, Alexander JS, Birch-Machin MA: Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. J Mol Diagn. 2006, 8: 312-319. 10.2353/jmoldx.2006.050112PubMedCentralCrossRefPubMed
21.
Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, Lim S, Issa MM, Flanders WD, Hosseini SH: mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci USA. 2005, 102: 719-724. 10.1073/pnas.0408894102PubMedCentralCrossRefPubMed
22.
Yu JJ, Yan T: Effect of mtDNA mutation on tumor malignant degree in patients with prostate cancer. Aging Male. 2010, 13: 159-165. 10.3109/13685530903536668CrossRefPubMed
23.
Leav I, Plescia J, Goel HL, Li J, Jiang Z, Cohen RJ, Languino LR, Altieri DC: Cytoprotective Mitochondrial Chaperone TRAP-1 As a Novel Molecular Target in Localized and Metastatic Prostate Cancer. Am J Pathol. 2010, 176: 393-401. 10.2353/ajpath.2010.090521PubMedCentralCrossRefPubMed
24.
Altieri DC, Languino LR, Lian JB, Stein JL, Leav I, van Wijnen AJ, Jiang Z, Stein GS: Prostate cancer regulatory networks. J Cell Biochem. 2009, 107: 845-852. 10.1002/jcb.22162PubMedCentralCrossRefPubMed
25.
de Bari L, Moro L, Passarella S: Prostate cancer cells metabolize d-lactate inside mitochondria via a D-lactate dehydrogenase which is more active and highly expressed than in normal cells. FEBS Lett. 2013, 587: 467-473. 10.1016/j.febslet.2013.01.011CrossRefPubMed
26.
Ragazzi M, de Biase D, Betts CM, Farnedi A, Ramadan SS, Tallini G, Reis-Filho JS, Eusebi V: Oncocytic carcinoma of the breast: frequency, morphology and follow-up. Hum Pathol. 2011, 42: 166-175. 10.1016/j.humpath.2010.07.014CrossRefPubMed
27.
Erbersdobler A, Fritz H, Schnoger S, Graefen M, Hammerer P, Huland H, Henke RP: Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. Eur Urol. 2002, 41: 40-46. 10.1016/S0302-2838(01)00021-5CrossRefPubMed
28.
Mirlacher M, Simon R: Recipient block TMA technique. Methods Mol Biol. 2010, 664: 37-44. 10.1007/978-1-60761-806-5_4CrossRefPubMed
29.
Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R, Tennstedt P, Muller J, Scholz L: ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res. 2011, 17: 5878-5888. 10.1158/1078-0432.CCR-11-1251CrossRefPubMed
30.
Burkhardt L, Fuchs S, Krohn A, Masser S, Mader M, Kluth M, Bachmann F, Huland H, Steuber T, Graefen M: CHD1 Is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res. 2013, 73: 2795-2805. 10.1158/0008-5472.CAN-12-1342CrossRefPubMed
31.
Kluth M, Hesse J, Heinl A, Krohn A, Steurer S, Sirma H, Simon R, Mayer PS, Schumacher U, Grupp K: Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol. 2013, 26: 975-983. 10.1038/modpathol.2012.236CrossRefPubMed
32.
Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, Kotschau D, Tennstedt P, Huang J, Gerhauser C: Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol. 2012, 181: 401-412. 10.1016/j.ajpath.2012.04.026CrossRefPubMed
33.
Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, Mihatsch MJ: Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol. 1996, 178: 437-441. 10.1002/(SICI)1096-9896(199604)178:4<437::AID-PATH484>3.0.CO;2-4CrossRefPubMed
34.
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C: The genomic complexity of primary human prostate cancer. Nature. 2011, 470: 214-220. 10.1038/nature09744PubMedCentralCrossRefPubMed
35.
Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, Ferrari M, Hernandez-Boussard T, Brooks JD, Pollack JR: Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 2007, 67: 8504-8510. 10.1158/0008-5472.CAN-07-0673CrossRefPubMed
36.
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B: Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010, 18: 11-22. 10.1016/j.ccr.2010.05.026PubMedCentralCrossRefPubMed
37.
Simon R, Mirlacher M, Sauter G: Immunohistochemical analysis of tissue microarrays. Methods Mol Biol. 2010, 664: 113-126. 10.1007/978-1-60761-806-5_12CrossRefPubMed
38.
Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M: Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol. 2008, 21: 1371-1378. 10.1038/modpathol.2008.104CrossRefPubMed
39.
Grupp K, Kohl S, Sirma H, Simon R, Steurer S, Becker A, Adam M, Izbicki J, Sauter G, Minner S: Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence. Mod Pathol. 2013, 26: 733-742. 10.1038/modpathol.2012.206CrossRefPubMed
40.
Ward PS, Thompson CB: Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012, 21: 297-308. 10.1016/j.ccr.2012.02.014PubMedCentralCrossRefPubMed
41.
Hsu PP, Sabatini DM: Cancer cell metabolism: Warburg and beyond. Cell. 2008, 134: 703-707. 10.1016/j.cell.2008.08.021CrossRefPubMed
42.
43.
Levine AJ, Puzio-Kuter AM: The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 2010, 330: 1340-1344. 10.1126/science.1193494CrossRefPubMed
44.
Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, Hatzivassiliou G, Elstrom RL, Thompson CB: The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene. 2005, 24: 4165-4173. 10.1038/sj.onc.1208622CrossRefPubMed
45.
Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB: Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004, 64: 3892-3899. 10.1158/0008-5472.CAN-03-2904CrossRefPubMed
46.
Deprez J, Vertommen D, Alessi DR, Hue L, Rider MH: Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. J Biol Chem. 1997, 272: 17269-17275. 10.1074/jbc.272.28.17269CrossRefPubMed
47.
Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N: Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 2001, 15: 1406-1418. 10.1101/gad.889901PubMedCentralCrossRefPubMed
48.
Kohn AD, Summers SA, Birnbaum MJ, Roth RA: Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem. 1996, 271: 31372-31378. 10.1074/jbc.271.49.31372CrossRefPubMed
49.
Wakil SJ, Porter JW, Gibson DM: Studies on the mechanism of fatty acid synthesis. I. Preparation and purification of an enzymes system for reconstruction of fatty acid synthesis. Biochim Biophys Acta. 1957, 24: 453-461.CrossRefPubMed
50.
Bentzinger CF, Romanino K, Cloetta D, Lin S, Mascarenhas JB, Oliveri F, Xia J, Casanova E, Costa CF, Brink M: Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab. 2008, 8: 411-424. 10.1016/j.cmet.2008.10.002CrossRefPubMed
51.
Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P: mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature. 2007, 450: 736-740. 10.1038/nature06322CrossRefPubMed
52.
Schieke SM, Phillips D, McCoy JP, Aponte AM, Shen RF, Balaban RS, Finkel T: The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J Biol Chem. 2006, 281: 27643-27652. 10.1074/jbc.M603536200CrossRefPubMed
53.
Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T: Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell. 2013, 23: 159-170. 10.1016/j.ccr.2013.01.002CrossRefPubMed
54.
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005, 310: 644-648. 10.1126/science.1117679CrossRefPubMed
55.
Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, Shah RB, Chinnaiyan AM: TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006, 66: 3396-3400. 10.1158/0008-5472.CAN-06-0168CrossRefPubMed
56.
Brase JC, Johannes M, Mannsperger H, Falth M, Metzger J, Kacprzyk LA, Andrasiuk T, Gade S, Meister M, Sirma H: TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer. 2011, 11: 507- 10.1186/1471-2407-11-507PubMedCentralCrossRefPubMed
57.
Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P, Rantala J, Alanen K, Nees M, Kallioniemi O: FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2010, 70: 6735-6745. 10.1158/0008-5472.CAN-10-0244CrossRefPubMed
58.
Jhavar S, Brewer D, Edwards S, Kote-Jarai Z, Attard G, Clark J, Flohr P, Christmas T, Thompson A, Parker M: Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int. 2009, 103: 1256-1269. 10.1111/j.1464-410X.2008.08200.xCrossRefPubMed
59.
Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G: Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis. 2010, 13: 311-315. 10.1038/pcan.2010.31CrossRefPubMed
60.
Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON: ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci USA. 2009, 106: 12465-12470. 10.1073/pnas.0905931106PubMedCentralCrossRefPubMed
61.
62.
Goo CK, Lim HY, Ho QS, Too HP, Clement MV, Wong KP: PTEN/Akt signaling controls mitochondrial respiratory capacity through 4E-BP1. PLoS One. 2012, 7: e45806- 10.1371/journal.pone.0045806PubMedCentralCrossRefPubMed
Metadata
Title
High mitochondria content is associated with prostate cancer disease progression
Authors
Katharina Grupp
Karolina Jedrzejewska
Maria Christina Tsourlakis
Christina Koop
Waldemar Wilczak
Meike Adam
Alexander Quaas
Guido Sauter
Ronald Simon
Jakob Robert Izbicki
Markus Graefen
Hartwig Huland
Thorsten Schlomm
Sarah Minner
Stefan Steurer
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2013
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-12-145

Other articles of this Issue 1/2013

Molecular Cancer 1/2013 Go to the issue

Review

Tumor glycolysis as a target for cancer therapy: progress and prospects

Research

Decreased fructose-1,6-bisphosphatase-2 expression promotes glycolysis and growth in gastric cancer cells

Research

Orthotopic transplantation of retinoblastoma cells into vitreous cavity of zebrafish for screening of anticancer drugs

Research

MiR-451 inhibits cell growth and invasion by targeting MIF and is associated with survival in nasopharyngeal carcinoma

Research

Reversal of chemosensitivity and induction of cell malignancy of a non-malignant prostate cancer cell line upon extracellular vesicle exposure

Research

Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits